NASDAQ$IXHL
Incannex Healthcare Inc · Q3 2026 earnings
Q3 2026 earnings · · Before market open
Briefing
Incannex Healthcare Inc reported its Q3 2026 financial results with continued net losses amid ongoing clinical development.
The company recorded zero revenue and a net loss of $3.9 million for the quarter ended March 31, 2026. Cash and cash equivalents increased significantly to $74.5 million following equity financings. Research and development expenses declined as certain trials completed, while general and administrative costs rose due to stock-based compensation.
- Revenue remained at zero as the company is still in clinical-stage development.
- Net loss for the quarter was $3.9 million, with EPS of $(0.35).
- Cash position strengthened to $74.5 million after registered direct offering and other financings.
- R&D expenses dropped sharply to $0.3 million following completion of key IHL-42X trials.
Headline financials
Revenue & EPS history
Incannex Healthcare Inc · Revenue · Quarterly
$0
Forward guidance
Company continues advancing IHL-42X, PSX-001 and IHL-675A programs with focus on regulatory pathways and Phase 2/3 studies.
Tailwinds
- FDA Fast Track designation for IHL-42X
- Positive Phase 2 results for PSX-001 and IHL-42X
- Strong cash runway exceeding 12 months
Headwinds
- Ongoing net losses and cash burn from R&D
- No commercial revenue expected until drug approvals
- Dependence on future equity or debt financings
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 5 quarterly earnings reports · overlaid with Q3 2026
-0.9%
Avg return
Earnings day
-3.8%
Avg return
5 days after
-12.2%
Avg return
30 days after
33%
2 / 6 earnings
Positive
+11.8%
Q2 2024
Best reaction
-11.7%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2026 | +1.8% | -5.1% | -1.8% | |
| Q1 2026 | -1.4% | -6.7% | +18.5% | |
| Q2 2025 | -0.9% | -9.8% | -58.8% | |
| Q1 2025 | -11.7% | -18.9% | -29.8% | |
| Q3 2024 | -5.2% | -16.5% | +8.5% | |
| Q2 2024 | +11.8% | +34.4% | -9.8% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro